Claritev (NYSE:CTEV) CEO Acquires $199,940.00 in Stock

Claritev (NYSE:CTEV) CEO Travis Dalton purchased 15,380 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The shares were purchased at an average cost of $13.00 per share, for a total transaction of $199,940.00. Following the purchase, the chief executive officer directly owned 24,952 shares in the company, valued at $324,376. This trade represents a 160.68% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Claritev Price Performance

NYSE:CTEV opened at $18.00 on Thursday. The firm has a 50-day moving average of $27.38 and a two-hundred day moving average of $45.74. The stock has a market cap of $297.18 million, a P/E ratio of -1.04 and a beta of 0.60. Claritev has a 1-year low of $12.04 and a 1-year high of $74.07.

Analyst Ratings Changes

A number of equities analysts have issued reports on CTEV shares. UBS Group reaffirmed a “buy” rating on shares of Claritev in a research report on Tuesday, February 24th. Guggenheim restated a “buy” rating on shares of Claritev in a research note on Tuesday, February 24th. Wells Fargo & Company set a $30.00 price objective on shares of Claritev and gave the company an “equal weight” rating in a research note on Tuesday, February 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Claritev in a research report on Monday, December 29th. Finally, Citigroup cut their target price on shares of Claritev from $63.00 to $21.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $29.67.

Institutional Trading of Claritev

Several institutional investors have recently added to or reduced their stakes in the business. State of Wyoming bought a new position in shares of Claritev in the 4th quarter worth about $25,000. Ameritas Investment Partners Inc. acquired a new stake in Claritev during the third quarter worth about $42,000. Legal & General Group Plc bought a new position in Claritev in the third quarter worth about $45,000. Invesco Ltd. boosted its stake in Claritev by 4.8% in the fourth quarter. Invesco Ltd. now owns 22,802 shares of the company’s stock valued at $975,000 after acquiring an additional 1,044 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new position in Claritev in the fourth quarter valued at approximately $45,000. Institutional investors own 87.15% of the company’s stock.

About Claritev

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.